China's Sinopharm says data 'better than expected' from it's COVID vaccine trial

  • Sinopharm's unit CNBG has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the UAE, Bahrain and Egypt
  • It did not offer details on the better-than-expected data, or specify which vaccine candidate the data are generated from

Reuters
Updated11 Nov 2020, 06:46 PM IST
Sinopharm
Sinopharm(REUTERS)

China National Pharmaceutical Group (Sinopharm) said on Wednesday the data from large-scale, late-stage clinical trials for its unit's COVID-19 vaccine are "better than expected".

Sinopharm's unit China National Biotec Group (CNBG) has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the United Arab Emirates, Bahrain and Egypt involving more 50,000 participants in total.

The trials are nearing their ends, Sinopharm said in a statement on Chinese social media WeChat.

It did not offer details on the better-than-expected data, or specify which vaccine candidate the data are generated from.


Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

Business NewsCompaniesNewsChina's Sinopharm says data 'better than expected' from it's COVID vaccine trial
MoreLess